←
David Segar605 posts
David Segar avatar

David Segar

@DaveSegar

medical director @Nudge. previously neurosurgeon/scientist @NeurosurgUCSF @MGBNeurosurgery

◷ Joined March 2011▧ 26 Photos and videos
David Segar avatar
David Segar@DaveSegar·22 Jul 2025

The first time I understood the impact of neuromodulation was while witnessing a deep brain stimulation surgery during my first year of medical school. What stuck with me--more than anything else--was the way the patient's face lit up when her symptoms disappeared. Surgical treatments can be world-changing, but they won't reach everyone. Imagine you could safely target those same parts of the brain, but without surgery. At @nudge, we're doing just that, by building non-invasive brain interfaces to deliver life-changing treatments to millions of people. Excited to see where we can take this.

Nudge@nudge22 Jul 2025

Half the world will experience a brain disorder in their lifetime. At @nudge, we're building brain interfaces that are safe, precise, and non-invasive to solve that problem. We've raised a $100M Series A led by @ThriveCapital and Greenoaks to go faster. We're hiring. Join us.

0:12
Sumner L Norman avatar
⟳ David Segar retweeted
Sumner L Norman@SumnerLN·Jun 26

It’s been a big week (month? year? decade?) for ultrasound and I’m getting dozens of DMs so I’m going to do another one of these “the science behind” threads. On this weeks’ edition: Aleph’s incredible images and the ultrasound science behind them. 🧵🔊

We recently obtained the highest-resolution 3D images of the human brain ever taken from outside the skull. This is the first look. Introducing Aleph, a research lab building brain interfaces for the telepathic future. (1/n)

0:13
Midjourney avatar
⟳ David Segar retweeted
Midjourney@midjourney·Jun 18

Announcing a new division of Midjourney called "Midjourney Medical"

2:23
Max Hodak avatar
⟳ David Segar retweeted
Max Hodak@maxhodak_·Jun 3

people truly don’t appreciate the coming health insurance apocalypse. as more substantial breakthroughs come out (and they are coming!) people will see outcomes totally unimaginable before. But the coverage won’t be there. I really need to write more on this topic

Becky Quick @BeckyQuick Jun 3

Post attachment
FutureHouse avatar
⟳ David Segar retweeted
FutureHouse@FutureHouseSF·May 19

We're pleased to share our first @Nature paper: Robin is the first multi-agent system for discovery in biology that integrates novel hypothesis generation with experimental data analysis in one continuous workflow. In this study, our team, including ophthalmologist @agreeb66, applied Robin to dry age-related macular degeneration, a leading cause of irreversible sight loss with limited treatment options. The system proposed drug-repurposing hypotheses, which were then tested experimentally in the lab. Robin developed the experimental strategy for therapeutic hypothesis generation, proposed follow-up experiments, and extracted actionable insights from the resulting data, including validation in primary human retinal pigment epithelium (RPE) stem cells. Robin also proposed a mechanism of enhancing RPE phagocytosis by modulating the cells circadian rhythm using an experimental drug, KL001, that has never before been used in humans or proposed for AMD. To our knowledge, this mechanism had not previously been proposed. This work points to the future of AI-enabled science: systems that connect insights across fields, surface new mechanisms, and turn existing knowledge into testable hypotheses. It also represents the broader opportunity FutureHouse is building toward: AI that helps science cross disciplinary boundaries and move from literature to experiment to discovery. nature.com/articles/s41586-0…

Anastasia Gamick avatar
⟳ David Segar retweeted
Anastasia Gamick@AGamick·May 18

NSF not only ran with the X-Labs concept, but committed $1.5B This is a bold and exciting opportunity. We want to find the scientists and entrepreneurs who want to make the most of this moment.

Post attachment
Jacques Carolan avatar
⟳ David Segar retweeted
Jacques Carolan@JacquesCarolan·Mar 16

I may by slightly biased, but I think this is one of the best jobs in the world! It would also be awesome to see incredible neurotech folks apply to this — huge opportunity for outsized impact. Please share widely!

The search for ARIA’s next cohort of Programme Directors has begun 🚀 As an ARIA PD, you will design and actively manage a ~£50M R&D programme within or around our opportunity spaces with the goal of unlocking scientific and technological breakthroughs that benefit everyone. There is no one way to be an ARIA PD – our existing cohorts come from a range of backgrounds, including academia, entrepreneurship, invention and industry, and have launched programmes in areas ranging from synthetic plants to multi-agent coordination to brain surgery-free neurotechnologies. Full applications will open in August 2026 for a May 2027 start date – over the coming months we’ll be running webinars and in-person events across the UK, Europe, the US and Asia where you’ll get the chance to engage directly with the ARIA team and learn more about the opportunity. Find out more about what it means to be a PD and register your interest to be the first to receive updates on the recruitment process: link.aria.org.uk/pdc3-x

Derya Unutmaz, MD avatar
⟳ David Segar retweeted
Derya Unutmaz, MD@DeryaTR_·20 Nov 2025

Until a few hours ago, creating this kind of scientific image would have required at least an hour of professional work. Now, with NanoBanana Pro, it only takes a simple prompt & less than 30 seconds! Prompt: “Describe in an illustration the events for a cytotoxic T cell recognizing & killing a cancer cell.”

Post attachment
Sam Altman avatar
⟳ David Segar retweeted
Sam Altman@sama·16 Nov 2025

This is exciting; I expect we are going to see a lot more things like this and it will be one of the most important impacts of AI. Congrats to the Future House team. edisonscientific.com/article…

Patrick Collison avatar
⟳ David Segar retweeted
Patrick Collison@patrickc·3 Nov 2025

An interesting trend we're noticing at Stripe: US startups are pulling ahead of their peers elsewhere. These charts show averaged revenue growth for software startups in each location. US startups typically grow somewhat faster than those elsewhere. However, since mid-2023, US companies have accelerated a lot. Interestingly, this is not just because of AI startups: if we strip those out, there's still a big divergence. Our leading hypothesis is that US startups (even those that aren't AI companies as such) are adopting new technologies (AI, stablecoins, etc.) faster than companies elsewhere. (This pattern of faster adoption among US companies was also seen with the internet itself.) Whatever the cause, the pattern is striking. [Methodological note: this pattern appears to hold beyond Europe as well.]

Post attachmentPost attachment
Jacques Carolan avatar
⟳ David Segar retweeted
Jacques Carolan@JacquesCarolan·27 Oct 2025

such incredible news: for the entire @uclh team, uk neurotech and most importantly for paul and the folks in the future who will benefit from this technology. huge congratulations to everyone involved 🚀

Neuralink@neuralink27 Oct 2025

🇬🇧 We’re excited to announce our first participant in the UK! Paul, who is paralyzed due to motor neuron disease, received his Neuralink implant at @uclh earlier this month and was able to control a computer with his thoughts just hours after surgery.

Post attachment
Sam Rodriques avatar
⟳ David Segar retweeted
Sam Rodriques@SGRodriques·22 Oct 2025

Cutting PhD spots is not the way for a country to win in a more competitive world.

Patrick Hsu@pdhsu21 Oct 2025

an absolute shame. @harvard cutting PhD admissions "The Organismic and Evolutionary Biology department will shrink its class size by roughly 75 percent to three new Ph.D. students [...] Molecular and Cellular Biology will reduce its figure to four new students, and Chemistry and Chemical Biology will go down to four or five admits" thecrimson.com/article/2025/…